Pulse Biosciences, Inc. (PLSE) Financial Analysis & Valuation | Quarter Chart
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue t... more
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $3.73B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Instruments & Supplies |
| Country | US | CEO | Paul Arthur LaViolette |
| IPO Date | 2016-05-18 | CAGR | — |
| Employees | 116 | Website | www.pulsebiosciences.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
PLSE chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $2.58B | P/E | -45.65 | Forward P/E | -46.71 | PEG | — |
| P/S | 133656.37 | P/B | 1591.4 | P/CF | -2092.54 | P/FCF | -2082.31 |
| Sales | $1.19M | Sales 1Y | inf% | Sales 3Y | -13266.67% | Sales 5Y | inf% |
| EPS | $-1.18 | EPS 1Y | 9.35% | EPS 3Y | -4.88% | EPS 5Y | -50% |
| Sales QoQ | 8.23% | EPS QoQ | 38.46% | Sales QoQ Avg | — | EPS QoQ Avg | 7.92% |
| Gross Margin | -21.6% | Operating Margin | -7007.76% | Profit Margin | -6755.78% | ROCE | -79.4% |
| ROA | -69% | ROE | -94% | Altman Z Score | 119.58 | Piotroski Score | 3 |
| Current Ratio | 9.63 | Quick Ratio | 9.61 | Cash Ratio | 9.26 | Op. CF Ratio | -3.03 |
| Debt/Equity | 0.07 | Debt/Assets | 0.06 | Lt Debt/Equity | 0.05 | Lt Debt/Cap. | 0.05 |
| Intrst Cov. | — | Inventory Turnover | 6.11 | Asset Turnover | 0.01 | Receivables Turnover | 9.71 |
| Enterprise Value | $2.58B | P/E Ratio | -45.65 |
| Forward P/E | -46.71 | PEG Ratio | — |
| P/S Ratio | 133656.37 | P/B Ratio | 1591.4 |
| P/CF Ratio | -2092.54 | P/FCF Ratio | -2082.31 |
| EPS | $-1.18 | EPS Growth 1Y | 9.35% |
| EPS Growth 3Y | -4.88% | EPS Growth 5Y | -50% |
| Revenue Growth 1Y | inf% | Gross Margin | -21.6% |
| Operating Margin | -7007.76% | Profit Margin | -6755.78% |
| ROE | -94% | ROA | -69% |
| ROCE | -79.4% | Current Ratio | 9.63 |
| Quick Ratio | 9.61 | Cash Ratio | 9.26 |
| Debt/Equity | 0.07 | Interest Coverage | — |
| Altman Z Score | 119.58 | Piotroski Score | 3 |
Pulse Biosciences, Inc. (PLSE) valuation & financials
Pulse Biosciences, Inc. (PLSE) has a market capitalization of $3.73B and trades at a price-to-earnings ratio of -45.6. It operates in the Healthcare sector (Medical - Instruments & Supplies).
Pulse Biosciences, Inc.'s revenue grew — over the last year.
Pulse Biosciences, Inc.'s next earnings report is scheduled for November 4, 2026 after market close (provider scheduled date); analysts estimate EPS of $-0.35. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)